CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma

NCT03213665

Clinical Trial Information

Trial Number: NCT03213665 (ClinicalTrials.gov)

Disease Type:

CNS Neoplasm (Primary Tumor) - Miscellaneous
CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma
Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma) - Miscellaneous
Hematopoietic Neoplasm/Lymphoma - Non-Hodgkin Lymphoma
Miscellaneous Neoplasm - Solid Tumor

Trial Title:

"NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex"

Study ID:

APEC1621C

Images are available?:

Is this a NCI-MATCH Trial?:

NCT03213691

Clinical Trial Information

Trial Number: NCT03213691 (ClinicalTrials.gov)

Disease Type:

CNS Neoplasm (Primary Tumor) - Miscellaneous
CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma
Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma) - Miscellaneous
Hematopoietic Neoplasm/Lymphoma - Non-Hodgkin Lymphoma
Miscellaneous Neoplasm - Solid Tumor

Trial Title:

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations

Study ID:

APEC1621E

Images are available?:

Is this a NCI-MATCH Trial?:

NCT00026312

Clinical Trial Information

Trial Number: NCT00026312 (ClinicalTrials.gov)

Disease Type:

CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma

Trial Title:

Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue

Study ID:

ANBL0032

Images are available?:

Is this a NCI-MATCH Trial?:

NCT00567567

Clinical Trial Information

Trial Number: NCT00567567 (ClinicalTrials.gov)

Disease Type:

CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma

Trial Title:

Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma

Study ID:

ANBL0532

Images are available?:

Is this a NCI-MATCH Trial?:

Datasets Linked to Trial

Title	Description
NCT00567567-D1	There is one dataset associated with the publication: NCT00567567-D1. USI is the patient identifier and blanks or "." represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning). NCT00567567-D1: There is one row for each patient enrolled on the study ANBL0532. The dataset provides the information necessary to reproduce the manuscript.

Title

Description

NCT00567567-D1

There is one dataset associated with the publication: NCT00567567-D1.
USI is the patient identifier and blanks or "." represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).
NCT00567567-D1: There is one row for each patient enrolled on the study ANBL0532. The dataset provides the information necessary to reproduce the manuscript.

NCT01798004

Clinical Trial Information

Trial Number: NCT01798004 (ClinicalTrials.gov)

Disease Type:

CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma

Trial Title:

Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma

Study ID:

ANBL12P1

Images are available?:

Is this a NCI-MATCH Trial?:

NCT00070200

Clinical Trial Information

Trial Number: NCT00070200 (ClinicalTrials.gov)

Disease Type:

CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma

Trial Title:

A Pilot Induction Regimen Incorporating Topotecan for Treatment of Newly Diagnosed High Risk Neuroblastoma

Study ID:

ANBL02P1

Images are available?:

Is this a NCI-MATCH Trial?:

NCT00004188

Clinical Trial Information

Trial Number: NCT00004188 (ClinicalTrials.gov)

Disease Type:

CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma

Trial Title:

A Randomized Study of Purged Versus Unpurged Peripheral Blood Stem Cell Transplant Following Dose Intensive Induction Therapy for High Risk Neuroblastoma

Study ID:

A3973

Images are available?:

Is this a NCI-MATCH Trial?:

NCT00499616

Clinical Trial Information

Trial Number: NCT00499616 (ClinicalTrials.gov)

Disease Type:

CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma

Trial Title:

Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma

Study ID:

ANBL0531

Images are available?:

Is this a NCI-MATCH Trial?:

Datasets Linked to Trial

Title	Description
NCT00499616-D7	There are two datasets associated with the publication: NCT00499616‐D6 and NCT00499616‐D7. USI is the patient identifier in all datasets. Blanks represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning). NCT00499616-D7: There is one row for each adverse event experienced during cycles 1‐8 and retrieval therapy cycles 9‐14. Adverse events that were not graded as moderate, life threatening, or the cause of death were excluded.
NCT00499616-D6	There are two datasets associated with the publication: NCT00499616‐D6 and NCT00499616‐D7. USI is the patient identifier in all datasets. Blanks represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning). NCT00499616‐D6: There is one row for each patient enrolled on ANBL0531. The dataset provided provides the information necessary to reproduce the manuscript, except for the toxicities.
NCT00499616-D5	There are five datasets associated with the publication: NCT00499616-D1, NCT00499616-D2, NCT00499616-D3, NCT00499616-D4, NCT00499616-D5. USI is the patient identifier in all datasets. Blanks and '.' represent missing data or not applicable for analyses. For various reasons, data may contain slight discrepancies from that reported in the publication. NCT00499616-D5: Each row represents one intermediate risk stage 4S patient enrolled on ANBL0531. The dataset provided, when used with other datasets submitted under this NCT number, supplies the information necessary to reproduce patient baseline characteristics, survival, and other results of the manuscript.
NCT00499616-D4	There are five datasets associated with the publication: NCT00499616-D1, NCT00499616-D2, NCT00499616-D3, NCT00499616-D4, NCT00499616-D5. USI is the patient identifier in all datasets. Blanks and '.' represent missing data or not applicable for analyses. For various reasons, data may contain slight discrepancies from that reported in the publication. NCT00499616-D4: Each row represents one intermediate risk stage 4S patient enrolled on ANBL0531 and the treatment they received.
NCT00499616-D3	There are five datasets associated with the publication: NCT00499616-D1, NCT00499616-D2, NCT00499616-D3, NCT00499616-D4, NCT00499616-D5. USI is the patient identifier in all datasets. Blanks and '.' represent missing data or not applicable for analyses. For various reasons, data may contain slight discrepancies from that reported in the publication. NCT00499616-D3: Data required for replicating Table 4 in the publication.
NCT00499616-D2	There are five datasets associated with the publication: NCT00499616-D1, NCT00499616-D2, NCT00499616-D3, NCT00499616-D4, NCT00499616-D5. USI is the patient identifier in all datasets. Blanks and '.' represent missing data or not applicable for analyses. For various reasons, data may contain slight discrepancies from that reported in the publication. NCT00499616-D2: Each row represents one baseline abnormality reported on ANBL0531.
NCT00499616-D1	There are five datasets associated with the publication: NCT00499616-D1, NCT00499616-D2, NCT00499616-D3, NCT00499616-D4, NCT00499616-D5. USI is the patient identifier in all datasets. Blanks and '.' represent missing data or not applicable for analyses. For various reasons, data may contain slight discrepancies from that reported in the publication. NCT00499616-D1: There is one row for each stage 4S patient enrolled on ANBL00B1. The dataset provided, when used with other datasets submitted under this NCT number, provides the information necessary to reproduce patient baseline characteristics, survival, and other results of the manuscript.

NCT00033293

Clinical Trial Information

Trial Number: NCT00033293 (ClinicalTrials.gov)

Disease Type:

CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma

Trial Title:

A Pilot Study Randomized Trial of Intravenous Gammaglobulin Therapy for Patients With Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated With Chemotherapy and Prednisone

Study ID:

ANBL00P3

Images are available?:

Is this a NCI-MATCH Trial?:

Datasets Linked to Trial

Title	Description
NCT00033293-D3	There are three datasets: NCT00033293-D1 NCT00033293-D2 and NCT00033293-D3 for PMID 29376112. USI is the patient identifier in all datasets. NCT00033293-D3 There is one row for each patient used to create Supplemental Table 2 of the manuscript. The dataset provides the information necessary to reproduce the distribution of OMA scores by symptom and time point.
NCT00033293-D2	There are three datasets: NCT00033293-D1 NCT00033293-D2 and NCT00033293-D3 for PMID 29376112. USI is the patient identifier in all datasets. NCT00033293-D2 Each row represents one adverse event used in the manuscript or one row per patient if no adverse event of interest was experienced. These data provide specific incidence of adverse events of interest to recreate Table 3 found in the manuscript.
NCT00033293-D1	There are three datasets: NCT00033293-D1 NCT00033293-D2 and NCT00033293-D3 for PMID 29376112. USI is the patient identifier in all datasets. NCT00033293-D1 There is one row for each patient enrolled on ANBL00P3. The dataset provides the information necessary to reproduce patient baseline characteristics, evaluability, treatment received, disease response, and survival.

NCT01041638

Clinical Trial Information

Trial Number: NCT01041638 (ClinicalTrials.gov)

Disease Type:

CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma

Trial Title:

A Comprehensive Safety Trial of Chimeric Antibody 14.18 (Ch14.18) With GM-CSF, IL-2 and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy

Study ID:

ANBL0931

Images are available?:

Is this a NCI-MATCH Trial?:

Datasets Linked to Trial

Title	Description
NCT01041638-D4	Each row represents the highest of grade one and two adverse events per patient, per reporting period. This dataset can be used with NCT01041638-D1 to create supplemental table 1.
NCT01041638-D3	There is one row for each patient enrolled on ANBL0931. These data can be used to reproduce pharmacokinetics analysis presented in the manuscript.
NCT01041638-D2	Each row represents one adverse event used in the manuscript. These data provide specific incidence of adverse events of interest.
NCT01041638-D1	The data and analysis for the results reported in Table 6 in the paper published was completed externally. Given the limited access to the original data, Table 6 subsequently has not been able to be replicated. There is one row for each patient enrolled on ANBL0931. The dataset provides the information necessary to reproduce patient baseline characteristics, disease outcome, and survival for patients on ANBL0931.

Subscribe to CNS-excluded Nervous System Neoplasm and Disorder - Neuroblastoma

Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security

U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov

NIH…Turning Discovery Into Health^®